Patent · US Active

Monoclonal anti-CD95L antibody

US10428154B2 · kind B2 · utility

0Cited by

1References

10Claims

0Family size

Assignee

APOGENIX AG · DE

Inventors

Christian Gieffers · Dossenheim, DE
Oliver Hill · Neckarsteinach, DE
Meinolf Thiemann · Schriesheim, DE
Jaromir Sykora · Heppenheim, DE
Christian Merz · Neckarsteinach, DE
Tim SCHNYDER · Igersheim, DE
Harald Fricke · Mannheim, DE

Key dates

Filing date	Mar 21, 2018
Grant date	Oct 1, 2019
Priority date	—
Expiry date	Mar 21, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.